Clinical Trials in Boston

Showing 3641-3660 of 17,836 trials

Access Cannulation Trial II

NCT05490225

This is a pivotal, interventional, prospective, single-arm, open-label, multi-site clinical investigation intended to support FDA clearance of the study device based on the safety and efficacy of the device in cannulating arteriovenous fistulas (AVFs) for hemodialysis procedures.

Dialysis; ComplicationsVascular Access Complication

Voyager Biomedical100 participantsStarted Apr 2025

Dothan, Alabama, United States • Riverside, California, United States • Boston, Massachusetts, United States +5 more locations

COMPLETEDPhase 2< 1 mile

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

NCT05983770

This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.

Kidney Transplant Rejection

Eledon Pharmaceuticals127 participantsStarted Aug 2023

Los Angeles, California, United States • Los Angeles, California, United States • Orange, California, United States +40 more locations

Access Cannulation Trial II

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Find Trials by Condition in Boston

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

Uniport and Multiport Epidural Catheters in Post-surgical Patients

Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

Individualizing Treatment for Asthma in Primary Care (Full Study)

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Ear-Seizure Detection (EarSD) Study

Musical Playlist of the Grief Journey

Evaluation of the Clinical Performance of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Stryker's Surgeon iD Mandible Reconstruction Plates: A Retrospective Post Market Follow Up